or Try an Advanced Search...

    Hematologic Malignancies Stocks List

    Symbol Grade Name % Change
    AFMD F Affimed Therapeutics B.V. -2.94
    TCRX F TScan Therapeutics, Inc. -4.37
    APTO F Aptose Biosciences, Inc. -10.66
    HOWL F Werewolf Therapeutics, Inc. 8.54
    FATE F Fate Therapeutics, Inc. -6.76
    INMB F INmune Bio Inc. 4.39
    CLLS F Cellectis S.A. -2.62
    CRBU D Caribou Biosciences, Inc. 1.02
    SLS D SELLAS Life Sciences Group, Inc. -1.61
    KYMR D Kymera Therapeutics, Inc. -1.23
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Solid Tumors Biopharmaceutical Cancer Medicine Biotechnology Clinical Medicine Tumors Of The Hematopoietic And Lymphoid Tissues Acute Myeloid Leukemia CD19 Immune System Life Sciences Blastoma Cancer Immunotherapy Cancer Treatment Chronic Lymphocytic Leukemia Glioblastoma Immunology Immunotherapies Immunotherapy Leukemia

    Related ETFs - A few ETFs which own one or more of the above listed Hematologic Malignancies stocks.

    Symbol Grade Name Weight
    IWC B iShares Microcap ETF 0.03
    AVSC B Avantis U.S. Small Cap Equity ETF 0.01
    VTWG B Vanguard Russell 2000 Growth ETF 0.01
    VTI A Vanguard Total Stock Market ETF 0.0
    DFAC A Dimensional U.S. Core Equity 2 ETF 0.0
    View all Hematologic Malignancies ETFs...
    Compare ETFs
    Compare IWC to AVSC Compare IWC to VTWG Compare VTI to DFAC

        Hematologic Malignancies Stocks Recent News

        Date Stock Title
        Nov 20 FATE Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
        Nov 20 CRBU Caribou Biosciences to Participate in Upcoming Investor Conferences
        Nov 20 HOWL Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
        Nov 20 APTO Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
        Nov 19 AFMD Is Affimed N.V. (AFMD) the Best German Stock to Buy Now?
        Nov 19 FATE Wall Street Breakfast Podcast: Fate Therapeutics Rises On Lupus Drug Data
        Nov 18 FATE Fate Therapeutics Shares Rise After 'Promising' Lupus Treatment Results
        Nov 18 FATE Fate stock rallies 37% on positive Phase 1 data for FT819, FT522
        Nov 18 FATE Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
        Nov 18 FATE Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
        Nov 16 SLS We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate
        Nov 15 FATE Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
        Nov 15 AFMD Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ...
        Related Industries: Biotechnology
        Related Stock Lists: Biotechnology Cancer Solid Tumors Advanced Solid Tumors Biopharmaceutical Cancer Immunotherapy Cancer Treatment Checkpoint Inhibitor Disease Health Sciences Immune System Immunotherapy Life Sciences Lymphoma Metastatic Solid Tumors Precision Medicine Residual Disease Treatment Of Cancer Tumors Of The Hematopoietic And Lymphoid Tissues
        Hematologic Malignancies

        Hematologic malignancies are cancers of the blood, bone marrow, and lymphatic system. These cancers can affect the production and function of blood cells, leading to a variety of symptoms and complications. Common types of hematologic malignancies include leukemia, lymphoma, and multiple myeloma. Treatment for hematologic malignancies may include chemotherapy, radiation therapy, stem cell transplant, and targeted therapy.

        Browse All Tags